The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort.
 
Matteo Repetto
Travel, Accommodations, Expenses - Sanofi
 
Allison L. Richards
No Relationships to Disclose
 
Monica F Chen
Stock and Other Ownership Interests - Nordisk
 
Yingjie Zhu
No Relationships to Disclose
 
Pier Selenica
No Relationships to Disclose
 
Andrea Gazzo
Consulting or Advisory Role - enGenome
 
Patrick Lee
No Relationships to Disclose
 
Adam Price
No Relationships to Disclose
 
Soo-Ryum Yang
Honoraria - Prime Education
Consulting or Advisory Role - InVitae
 
Antonio Marra
No Relationships to Disclose
 
Angela Rose Brannon
Stock and Other Ownership Interests - Johnson & Johnson
 
Ezra Rosen
No Relationships to Disclose
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Noura J. Choudhury
Consulting or Advisory Role - G1 Therapeutics; Sanofi
Research Funding - Abbvie (Inst); Amgen (Inst); Harpoon therapeutics (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Wolters Kluwer (Pocket Oncology).
 
Jorge S. Reis-Filho
Leadership - Grupo Oncoclinicas
Stock and Other Ownership Interests - PAIGE.AI; Repare Therapeutics
Consulting or Advisory Role - Bain Capital Life Sciences; Genentech/Roche; Goldman Sachs; Invicro; Novartis; Paige.AI; Personalis; Repare Therapeutics; SAGA Diagnostics; Ventana Medical Systems; Volition RX
 
Mark Donoghue
No Relationships to Disclose